Actelion submits European app for macitentan; Sarepta inks exon-skipping collaboration pact with scientist;

Conversations on Twitter :

 @FierceBiotech: Trending on FierceBiotech.com: Blockbuster buzz: 15 top therapies in late-stage development. Special Report | Follow @FierceBiotech

 @JohnCFierce: AstraZeneca, Pfizer partner on $100M drug research collaboration project. Report | Follow @JohnCFierce

 @RyanMFierce: Averting the next bapi bust? J&J exec prescribes new approach to Alzheimer's drug development. Story | Follow @RyanMFierce

> Actelion ($ATLN) has submitted an application for its next-gen PAH therapy macitentan with the EMA. Release

> H3 Biomedicine in Cambridge, MA, has been expanding. The biotech says it expects to end 2013 with 75 staffers, more than twice the number of employees it had at the end of last year. Story

> Sarepta ($SRPT) has forced a collaboration with a University College London scientist for the development of an additional exon-skipping drug targeting exon 53, its fourth program in development. News

> OXiGENE ($OXGN) says the FDA has granted OXi4503 orphan designation for the treatment of acute myelogenous leukemia. Release

Pharma News

@FiercePharma: Pfizer slashes Viagra prices in Canada to compete with new generics. Cut = 25%. News | Follow @FiercePharma

> Roche to Cochrane critics: Let's compromise on Tamiflu data. News

> Ranbaxy trips over generic Lipitor. Story

> GSK socks $1B into emerging markets consumer business. Report

Medical Device News

 @FierceMedDev: Illumina gains legal means to keep fighting a patent claim against Complete Genomics. News | Follow @FierceMedDev

 @MarkHFierce: Volcano Corp., a rumored acquisition target, has itself acquired a company. More | Follow @MarkHFierce

 @DamianFierce: Innovent Biologics is moving into WuXi PharmaTech's backyard with a new Chinese plant. Report | Follow @DamianFierce

> Sorin commits $5.4M to percutaneous mitral valve replacement startup. Article

> Report: Baxter close to paying $4B for dialysis rival Gambro. More

> Analyst: St. Jude's woe is good news for Boston Scientific. News

Biotech IT News

> Eisai's H3 Bio leans on bioinformatics as cancer researcher expands. Report

> NIH taps Northrop Grumman for $30M bioinformatics project. Article

> J&J exec prescribes adaptive approach to Alzheimer's drug development. Story

CRO News

> U.K. wants CRO input on clinical trial reforms. Report

> QPS boosts Phase I capabilities in Netherlands. News

> Innovent targets WuXi with biologics plan. Story

> ShangPharma stumbles over increased costs in Q3. Article

And Finally… In the Dec. 12 issue of The Journal of the American Medical Association, two Johns Hopkins faculty members say that a dwindling role for government and drug company funding of basic biomedical research will spur scientists to hunt "innovative" kinds of private investment. Release

 

Suggested Articles

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.

FDA staff took the action in response to cases of early growth plate closure in children on the retinoic acid receptor gamma agonist.

The CTAD presentation cleared up some questions about the data set without delivering a telling blow for either side of the debate.